• Trump to impose 0% tariffs on generic medicines for two years, increasing to 200% thereafter.
• Indian pharmaceutical exports significantly impacted, accounting for 47% of US generic prescriptions.
• Experts warn of potential price hikes and shortages of low-cost medicines in the US.
• Significant challenges foreseen for Indian companies dependent on US market.
• Pharmaceutical industry urged to adjust strategies amid tariff uncertainties.

US President Donald Trump announced a phased tariff regime on imported generic medicines, stating that these drugs will remain free of tariffs for the next two years, with tariffs increasing to 100% starting in August 2028, and reaching 200% by August 2029 if production is not relocated to the United States. The move aims to encourage domestic pharmaceutical manufacturing and bolster American jobs, according to Indiatimes.

This new tariff policy could have severe implications for India's pharmaceutical industry, which is a major supplier of generic medicines to the US market. The country exported approximately $9.7 billion worth of pharmaceuticals to the US in 2025, equating to about 47% of the generics dispensed in the US. Such tariffs could threaten competitive pricing, potentially increasing healthcare costs for millions of Americans who rely on these affordable medications, especially given the already low profit margins of generic drug manufacturers, as highlighted by Indiatimes and Los Angeles Times.

Health policy experts are concerned that merely imposing tariffs may not be sufficient to induce manufacturers to move operations back to the US, as the cost differences in production can significantly affect price structures. The tariffs are perceived as a measure that may lead to higher medicine prices and potential shortages unless companies adjust swiftly to the new regulations. This concern is echoed by studies noting that generic medicines account for over 90% of prescriptions in the US, which makes the affordability of these drugs crucial for public health, according to CBS News and Los Angeles Times.

The tariffs could prompt some producers to reconsider their presence in the US market entirely, leading to decisions to focus on higher-margin products rather than essential generics. Analysts warn that high tariffs could alternatively drive prices up for consumers, further complicating access to necessary medications. Such strategic shifts could affect companies that have historically relied on the US market, as noted by experts from Indiatimes and CBS News.

The impending tariffs place Indian pharmaceutical companies in a precarious position as many of them generate substantial revenue from the US. The risk of these companies facing severe losses is high, particularly since generic medicines often operate on low margins and cannot easily absorb the cost of increased tariffs. This is compounded by the complex logistics of relocating pharmaceutical manufacturing, which requires significant investments and compliance with regulatory standards, according to Indiatimes and Indiatimes.